Vycor Medical Inc.

Vycor Medical, Inc. (OTC: VYCO) is a medical device company that has developed ViewSite Brain Access System (VBAS) — a minimally invasive neurosurgical retractor and access device that enables surgeons to access deep brain structures through a smaller cranial incision and with less brain tissue displacement than conventional neurosurgical retractors, potentially reducing surgical trauma, improving patient outcomes, and expanding the range of brain lesions amenable to safe surgical resection. According to its website at vycormedical.com, the VBAS device uses a novel circular, tapered tube design that gently separates brain tissue as it is inserted to the target depth rather than compressing and displacing brain tissue laterally as conventional flat-blade retractors do — providing a surgical access corridor to deep brain tumors, hematomas, and other lesions with potentially less tissue trauma and better surgical visualization than traditional approaches.

Vycor Medical's VBAS neurosurgical access technology, described at vycormedical.com, has received FDA 510(k) clearance for use as a surgical access device in neurosurgical procedures, enabling Vycor to market the device to neurosurgeons performing intracranial tumor removal, hematoma evacuation, and other surgical procedures requiring access to deep brain structures. The device's minimally invasive design — which uses a compact, tubular access corridor rather than the large cranial opening and wide tissue retraction of traditional craniotomy approaches — enables neurosurgeons to perform procedures through smaller skull openings with potentially less cortical surface exposure and reduced risk of damage to surrounding eloquent cortex compared to conventional approaches. The VBAS has been used in clinical neurosurgical practice at academic medical centers and neurosurgical programs where the device's design characteristics have attracted interest from neurosurgeons seeking less invasive alternatives for appropriate brain surgery cases.

Vycor Medical pursues the commercialization of its VBAS neurosurgical access device through direct marketing to neurosurgeons and neurosurgical programs at academic medical centers and community hospitals, alongside partnership arrangements with neurosurgical equipment distributors who provide broader market coverage. According to vycormedical.com, the company's commercialization strategy focuses on building clinical adoption of the VBAS among neurosurgeons who find value in the device's minimally invasive design characteristics for appropriate surgical indications, supported by clinical evidence from published case series and peer-reviewed articles documenting the VBAS's surgical performance in neurosurgical procedures. Vycor Medical's combination of minimally invasive neurosurgical access device, FDA-cleared neurosurgical retractor technology, academic medical center clinical use, commercialization stage positioning, and OTC-listed public company structure reflects its participation in the specialized neurosurgical device market.